The value of innovation: The economics of targeted drugs for cancer

Targeted Oncology

Volumn 2, Issue 2, 2007, Pages 113-119

  Tigue, Cara C ^a,b   Fitzner, Karen A ^a   Alkhatib, Motasem ^a   Schmid, Eric ^a   Bennett, Charles L ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer; Health economics; Pharmaceutical cost; Targeted drugs

Indexed keywords

EID: 34147218318     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-007-0043-8     Document Type: Review

References (50)

1. Berenson A (2006) A cancer drug shows promise, at a price that many can't pay. In: New York Times. http://www.nytimes.com/2006/02/15/business/15drug. html?ei=5090&en=62aabaec5acffa8. Accessed 7 Dec 2006
2. Schulman KA, Glick HA, Yabroff R, Eisenberg JM (1995) Introduction to clinical economics: assessment of cancer therapies. J Natl Cancer Inst Monographs 9:1-9
3. Cohen S (2004) Benefits of extending medicare coverage to all oral anti-cancer drugs. J Undergrad Res 5(6)
4. Bicknell R (2005) The realisation of targeted antitumour therapy. Br J Cancer 92(Suppl 1):S2-S5
5. Segota E, Bukowski RM (2004) The promise of targeted therapy: cancer drugs become more specific. Clevel Clin J Med 71(7):551-560
6. Culliton B (2006) Science for life: a conversation with Nobel Laureate David Baltimore. Health Affairs - Web Exclusive, 16 May:w235-w240
7. Andersen MR et al (2004) Examining the cost-effectiveness of cancer screening promotion. Cancer 101(Suppl 5):1229-1238
8. Schrag D (2004) The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351(4):317-319
9. Klepper B, Pauker D (2006) Medicare's drug plan: huge price disparities for common cancer drugs. Community Oncology 3(12):753-755
10. Bowman J, Rousseau A, Silk D, Harrison C (2006) Access to cancer drugs in medicare part D: formulary placement and beneficiary cost sharing in 2006. Health Aff 25(5):1240-1248
11. National Cancer Institute, US National Institutes of Health (2006) Dictionary of Cancer Terms. http://www.cancer.gov/Templates/db_alpha.aspx?print= 1&cdrid=270742. Accessed 11 Dec 2006
12. Kaiser Family Foundation (2006) New York Times Examines Concerns Over High Cost of Cancer Medication Avastin. In: Kaisernetwork.org. Daily Health Policy Report - Prescription Drugs. http://www.kaisernetwork.org/daily_reports/ rep_index.cfm?hint=3&DR_ID=35433. Accessed 13 Dec 2006
13. Meropol NJ, Schulman KA (2007) Cost of cancer care: issues and implications. J Clin Oncol 25(2):180-186
14. Herper M (2004) Cancer's Cost Crisis. In: Forbes.com. http://www.forbes.com/technology/2004/06/08/cx_mh_0608costs.html. Accessed 7 Feb 2007
15. Yabroff KR et al (2007) Patient time costs associated with cancer care. J Natl Cancer Inst 99(1):14-23
16. Di Masi J, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25(2):209-216
17. Graham JD et al (1998) Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 19:125-152
18. Avastin package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2006/125085s085lbl.pdf
19. Campath Package Insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2006/103948s5065lbl.pdf
20. Erbitux package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2006/125084s046LBL.pdf
21. Herceptin package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2006/103792s5150lbl.pdf
22. Bexxar package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2004/125011_0024lbl.pdf
23. Rituxan package insert. Genentech website. http://www.gene.com/gene/ products/information/pdf/rituxan_prescribing.pdf
24. Mylotarg package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2006/021174s020lbl.pdf
25. Zevalin package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2005/125019_0092lbl.pdf
26. Vectibix package insert. Amgen Website. http://wwwext.amgen.com/pdfs/ products/vectibix_pi.pdf
27. Gleevec package insert. Novartis Website. http://www.pharma.us.novartis. com/product/pi/pdf/gleevec_tabs.pdf
28. Iressa package insert. AstraZeneca Website. http://www.astrazeneca_us. com/pi/iressa.pdf
29. Tarceva package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2005/021743s003lbl.pdf
30. Velcade package insert. FDA Website. http://www.fda.gov/cder/foi/label/ 2006/021602s010lbl.pdf
31. Nexavar package insert. http://www.fda.gov/cder/foi/label/2005/021923lbl. pdf
32. Sutent package insert. http://www.pfizer.com/pfizer/download/uspi_sutent. pdf
33. Sprycel package insert. http://www.bms.com/cgi_bin/anybin.pl?sql= select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=113&key=PPI
34. Mann B (2004) Triumph of Hope Over Reason. http://www.fool.com/investing/ small_cap/2004/09/01/triumph_of_hope_over_reason.aspx Accessed 18 Jan 2007
35. Fierce Biotech (2006) Amgen launches price war on Vectibix OK. In: Drug Discovery, Sept 28. http://www.fiercebiotech.com/story/ amgen_launches_price_war_on_vectibix_ok/2006_09_28. Accessed 18 Jan 2007
36. Genzyme g Care Newsletter Volume 7 (2005) http://www.genzymegenetics.com/ pdf/gene_p_payors_newsletter%209_03.pdf Accessed 18 Jan 2007
37. Gallagher T (2007) http://cogentpassion.blogspot.com/2006/06/ i_bought_onxx_onyx_pharm.html Accessed 18 Jan 2007
38. Pharma Times (2006) B-MS wins US OK for leukaemia drug Sprycel. In: World News, June 30. http://www.pharmatimes.com/WorldNews/Articles/9141_BMS_Sprycel. aspx?src=PTNews_10049 Accessed 18 Jan 2007
39. US Department of Health and Human Services (2004) Medicare to Extend Access to Certain Drugs for Beneficiaries with Serious and Chronic Illnesses. http://www.dhhs.gov/news/press/2004pres/20040624.html Accessed 18 Jan 2007
40. American Cancer Society (2005) A Better Drug for Relapsed Multiple Myeloma. http://www.cancer.org/docroot/NWS/content/ NWS_1_1x_A_Better_Drug_for_Relapsed_Multiple_Myeloma.asp Accessed 18 Jan 2007
41. Biopeer (2006) FDA approves Pfizer's new cancer drug. http://www.biopeer.com/biopeer/2006/01/fda_approves_pf.html Accessed 18 Jan 2007
42. Berenson A (2005) Cancer Drugs Offer Hope, but at a Huge Expense. In: New York Times, July 12. http://www.nytimes.com/2005/07/12/business/12cancer.html? ex=1278820800&en=1eb889752ca5eb49&ei=5088 Accessed 18 Jan 2007
43. Medical News Today (2006) UK Court Decides Health Trust Cannot Cherry Pick Herceptin Users. http://www.medicalnewstoday.com/healthnews.php?newsid= 41514 Accessed 18 Jan 2007
44. Tortora A (2002) The Cure and the Cost: Medical breakthroughs promise to save lives. Can we afford them? In: Cincinnati Business Courier, June 14. http://cincinnati.bizjournals.com/cincinnati/stories/2002/06/17/story3.html Accessed 18 Jan 2007
45. Timmerman L (2003) Corixa wins full reimbursement for lymphoma drug. In: The Seattle Times. http://archives.seattletimes.nwsource.com/cgi_bin/texis.cgi/ web/vortex/display?slug=corixa12&date=20030912 Accessed 18 Jan 2007
46. Patel J (2006) Korean A-7 Prices Compared to U.S. Prices. In: Drug Development, July 31. http://www.cptech.org/blogs/drugdevelopment/2006/07/ korean_7_prices_compared_to_us_prices_31.html Accessed 18 Jan 2007
47. Pringle E (2006) Genentech and Biogen Legal Troubles-When It Rains It Pours. http://www.lawyersandsettlements.com/articles/rituxan.html Accessed 18 Jan 2007
48. Tamir O, Rabinovich M, Shani M (2006) Year 2006 Update of the Israel National List of Health Services. http://www.ima.org.il/imaj/ar06sep_1.pdf Accessed 18 Jan 2007. IMAJ 8:595_600
49. NCD for Anti-Cancer Chemotherapy for Colorectal Cancer (110.17). Publication Number 12-3. Medicare Coverage Database. Centers for Medicare & Medicaid Services, U.S. Department of Health & Human Services. Available at http://www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=110.17&ncd_version= 1&basket=ncd. Accessed 4 Jan 2007
50. Clinical Coverage Criteria. Tufts Health Plan may authorize coverage of Tarceva- and Iressa. Available at: http://www.tuftshealthplan.com/providers/pdf/ pharmacy_criteria/Iressa.pdf. Accessed 8 Jan 2007